INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $490 | +101.6% | 26,386 | +20.1% | 0.00% | – |
Q2 2023 | $243 | -16.2% | 21,963 | +1.8% | 0.00% | – |
Q1 2023 | $290 | +9.4% | 21,579 | +0.7% | 0.00% | – |
Q4 2022 | $265 | -99.9% | 21,436 | +2.2% | 0.00% | – |
Q3 2022 | $293,000 | +8.5% | 20,970 | +7.4% | 0.00% | – |
Q2 2022 | $270,000 | -20.6% | 19,524 | -6.5% | 0.00% | – |
Q1 2022 | $340,000 | -23.9% | 20,891 | -23.8% | 0.00% | – |
Q4 2021 | $447,000 | -97.8% | 27,414 | -93.5% | 0.00% | -100.0% |
Q2 2020 | $20,144,000 | -41.7% | 420,459 | -23.4% | 0.00% | -40.0% |
Q1 2020 | $34,558,000 | -57.0% | 548,882 | -15.4% | 0.01% | -50.0% |
Q4 2019 | $80,422,000 | +527.4% | 648,984 | +235.9% | 0.01% | +400.0% |
Q3 2019 | $12,819,000 | -17.2% | 193,179 | -0.7% | 0.00% | 0.0% |
Q2 2019 | $15,482,000 | -29.5% | 194,573 | -0.9% | 0.00% | -33.3% |
Q1 2019 | $21,959,000 | +2863.4% | 196,308 | +2571.9% | 0.00% | – |
Q4 2018 | $741,000 | -25.3% | 7,347 | -6.4% | 0.00% | – |
Q3 2018 | $992,000 | +122.9% | 7,848 | +48.0% | 0.00% | – |
Q2 2018 | $445,000 | +39.1% | 5,301 | +1.9% | 0.00% | – |
Q1 2018 | $320,000 | -37.4% | 5,204 | -40.5% | 0.00% | – |
Q4 2017 | $511,000 | +78.0% | 8,753 | +76.9% | 0.00% | – |
Q3 2017 | $287,000 | -87.7% | 4,947 | -74.4% | 0.00% | – |
Q2 2017 | $2,342,000 | +1.9% | 19,341 | -4.8% | 0.00% | – |
Q1 2017 | $2,298,000 | -80.9% | 20,315 | -81.7% | 0.00% | -100.0% |
Q4 2016 | $12,029,000 | -33.4% | 110,715 | +0.9% | 0.00% | -50.0% |
Q3 2016 | $18,058,000 | +455.5% | 109,716 | +381.5% | 0.00% | +300.0% |
Q2 2016 | $3,251,000 | +7.3% | 22,785 | -3.4% | 0.00% | 0.0% |
Q1 2016 | $3,030,000 | -94.0% | 23,585 | -93.0% | 0.00% | -90.9% |
Q4 2015 | $50,444,000 | -10.4% | 337,756 | -0.5% | 0.01% | -15.4% |
Q3 2015 | $56,310,000 | -28.9% | 339,506 | +3.4% | 0.01% | -18.8% |
Q2 2015 | $79,246,000 | -30.6% | 328,303 | -19.0% | 0.02% | -33.3% |
Q1 2015 | $114,243,000 | +185.8% | 405,087 | +58.1% | 0.02% | +200.0% |
Q4 2014 | $39,968,000 | -35.7% | 256,202 | -2.4% | 0.01% | -42.9% |
Q3 2014 | $62,151,000 | -57.8% | 262,586 | -57.8% | 0.01% | -56.2% |
Q2 2014 | $147,191,000 | -21.4% | 622,030 | +9.6% | 0.03% | -23.8% |
Q1 2014 | $187,202,000 | – | 567,640 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |